%0 Journal Article
%A Braess, Jan
%A Amler, Susanne
%A Kreuzer, Karl-Anton
%A Spiekermann, Karsten
%A Lindemann, Hans Walter
%A Lengfelder, Eva
%A Graeven, Ullrich
%A Staib, Peter
%A Ludwig, Wolf-Dieter
%A Biersack, Harald
%A Ko, Yon-Dschun
%A Uppenkamp, Michael J
%A De Wit, Maike
%A Korsten, Stefan
%A Peceny, Rudolf
%A Gaska, Tobias
%A Schiel, Xaver
%A Behringer, Dirk M
%A Kiehl, Michael G
%A Zinngrebe, Bettina
%A Meckenstock, Gerald
%A Roemer, Eva
%A Medgenberg, Dirk
%A Spaeth-Schwalbe, Ernst
%A Massenkeil, Gero
%A Hindahl, Heidrun
%A Schwerdtfeger, Rainer
%A Trenn, Guido
%A Sauerland, Cristina
%A Koch, Raphael
%A Lablans, Martin
%A Faldum, Andreas
%A Görlich, Dennis
%A Bohlander, Stefan K
%A Schneider, Stephanie
%A Dufour, Annika
%A Buske, Christian
%A Fiegl, Michael
%A Subklewe, Marion
%A Braess, Birgit
%A Unterhalt, Michael
%A Baumgartner, Anja
%A Wörmann, Bernhard
%A Beelen, Dietrich
%A Hiddemann, Wolfgang
%T Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
%J Leukemia
%V 32
%N 12
%@ 1476-5551
%C London
%I Springer Nature
%M DKFZ-2018-01610
%P 2558-2572
%D 2018
%X Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = 'dose-dense') and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = 'standard'). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30275528
%R 10.1038/s41375-018-0268-9
%U https://inrepo02.dkfz.de/record/140855